TerminatedPhase 2NCT03000179
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Studying Adenocarcinoma of the small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Principal Investigator
- Dana Cardin, M.D.Vanderbilt-Ingram Cancer Center
- Intervention
- Avelumab(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (1)
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Collaborators
National Cancer Institute (NCI) · EMD Serono
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03000179 on ClinicalTrials.gov